ストックスクリーナーアプリを入手
13.52
2.17%
-0.2997
アフターアワーズ：
13.52
-0.0039
-0.03%
Homology Medicines Inc (FIXX) 最新ニュース
Antineutrophil Cytoplasmic Antibody (ANCA) Associated - openPR.com
Overview of Segmentation, Market Dynamics, and Competitive Landscape in the Mucolipidosis II Market - openPR.com
Emerging Sub-Segments Transforming the Lysosomal Enzyme Market Landscape - openPR.com
Form S-3 Q32 Bio Inc For: 17 July By Investing.com - Investing.com Canada
Q32 Bio (Nasdaq: QTTB) files to register 6.9M shares for resale - Stock Titan
Vitiligo Therapeutics Market Projected to Reach USD 2.28 Billion by 2032 - Yahoo Finance
Form 424B5 Q32 Bio Inc For: 15 July By Investing.com - Investing.com Canada
Form 424B5 Q32 Bio Inc For: 13 July By Investing.com - Investing.com Canada
Nucleic Acid Based Gene Therapy Market Report Evaluates Growth Drivers, Challenges And Market Dynamics - openPR.com
Q32 Bio (NASDAQ: QTTB) files $300M shelf; May 26 $55M placement noted - Stock Titan
Angel Yeast Releases 2025 Sustainability Report as Company Marks 40th Anniversary - Weekly Voice
Phenylketonuria Market Size, Share, Growth, Analysis, Report, 2034 - Straits Research
QTTB - Finviz
This Q32 Bio Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday - Sahm
Obesity Treatment Development: Challenges and Future Focus - Technology Networks
Mucolipidosis II Market Analysis: Major Segments, Strategic Developments, and Leading Companies - openPR.com
ATLAS VENTURE ASSOCIATES X L P Net WorthInsider Trades and Bio as of Apr 23, 2026 - Benzinga
Leading Companies Fueling Innovation and Growth in the Mucopolysaccharidosis Treatment Market - openPR.com
DEERFIELD PARTNERS L P Net WorthInsider Trades and Bio as of Apr 22, 2026 - Benzinga
Krabbe Disease Treatment Market Overview, Emerging Trends, and Key Player Analysis - openPR.com
Analysis of Key Market Segments Influencing the CRISPR Gene Editing Market - openPR.com
Deerfield Mgmt HIF L P Net WorthInsider Trades and Bio as of Apr 22, 2026 - Benzinga
Growth Patterns, Segment Analysis, and Competitive Approaches - openPR.com
Who’s Ahead in the Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market? Competitive Insights for 2026 - EIN News
Analysis of Market Segments and Major Growth Areas in the Nucleic Acid Based Gene Therapy Market - openPR.com
Biotech Expansion Accelerating Viral Vector Manufacturing Market Insights 2026–2035 - Weekly Voice
Q32 Bio Hits New HighRegrowth Signals? - RTTNews
Q32 Bio (QTTB) One Off Driven Q4 Profit Challenges Earnings Decline Narrative - Sahm
Q32 Bio Inc. 2025 Annual Report: Business Overview, Pipeline, Risks, and Intellectual Property Strategies - Minichart
Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight - Sahm
CNS Pharmaceuticals appoints Steven O’Loughlin as CFO, Dylan Wenke as CBO - TipRanks
CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic Transformation - Fox21Online
Brain cancer drug developer hires CFO, CTO and CBO in strategic reset - Stock Titan
$191.2 Million Achromatopsia Market Outlook, 2026-2032, Featuring Adverum Biotechnologies, Homology Medicines, Mattel, REGENXBIO, Sanofi and More - Yahoo Finance
Stoke Therapeutics Appoints Ian F. Smith as Chief Executive Officer - BioSpace
Editas Medicine nominates lead in vivo development candidate - BioWorld News
AAV for the Hereditary Retinal Diseases Clinical Trial - GlobeNewswire
OXB completes acquisition of remaining stake in US subsidiary - GlobeNewswire
Mucopolysaccharodisis Treatment Market Size & Share, 2033 - Market Data Forecast
Mammoth nominates development candidate for FCS and severe hypertriglyceridemia - BioWorld MedTech
Qatar’s $320bn wealth fund seeks to catch up on tech - businessreport.co.za
Stoke Therapeutics Announces CEO Transition - Business Wire
Q32 Bio Inc. (QTTB) reports earnings - qz.com
Versatope Adds New Board Members - PR Newswire
QTTB stock touches 52-week low at $2.59 amid market challenges - Investing.com
Homology Medicines (NASDAQ: FIXX)Share Price - intelligentinvestor.com.au
100 cell and gene therapy leaders to watch in 2025 - drugdiscoverytrends.com
Growth Trends in the CRISPR and Cas Gene Market: Industry Opportunities and Strategies to 2028 & 2033 - GlobeNewswire
Oxford BioMedica H1 Loss Narrows, Revenues Climb; Confirms FY24, Medium-term Outlook - RTTNews
Generation of a medicine food homology formula and its likely mechanism in treatment of microvascular angina - Frontiers
Could Q32 Bio’s ‘Skeleton Key’ Open the Door to New Treatments for an Array of Diseases? - University of Colorado Anschutz
QTTB reaches 52-week high, hitting $32.99 - Investing.com
Syncona melds two gene therapy biotechs for better shot at new nervous system treatments - BioPharma Dive
Phenylketonuria Pipeline and Clinical Trials Assessment 2024: - openPR.com
Timothy P Kelly Net WorthInsider Trades and Bio as of Apr 21, 2026 - Benzinga
Seamless Therapeutics Appoints Albert Seymour, Ph.D., as CEO - citybiz
Sensorium Therapeutics Appoints Sam Rasty as Chief Business Officer - PR Newswire
Homology Medicines Defeats Investor Suit Over Clinical Trial (1) - Bloomberg Law News
Q32 Bio Closes Merger with Homology Medicines - citybiz
Homology Medicines approves 1-for-18 reverse stock split By Investing.com - Investing.com India
Homology Medicines Declares Distribution to Common Stockholders | FIXX Stock News - Stock Titan
EDGAR Filing Documents for 0001193125-23-278325 - SEC.gov
Oxford Biomedica enters US through $180m Homology JV - BioProcess International
Q32 Bio Announces Publication of Preclinical Data in Molecular Therapy Demonstrating the Therapeutic Potential of Tissue-Targeted Complement Inhibitor ADX-097 for Complement-Mediated Diseases - PR Newswire
Analytical characterization of full, intermediate, and empty AAV capsidsGene Therapy - Nature
Neurogene Appoints Julie Jordan, M.D., as Chief Medical Officer - citybiz
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024 - Stock Titan
The definitive Boston biotech layoff tracker for 2023 - The Business Journals
Watkins Advises Homology Medicines in Merger Agreement With Q32 Bio - Latham & Watkins LLP
1.21%
1.07%
大文字化:
|
ボリューム (24 時間):